PMID- 16483745
OWN - NLM
STAT- MEDLINE
DCOM- 20060908
LR  - 20220409
IS  - 0920-9964 (Print)
IS  - 0920-9964 (Linking)
VI  - 84
IP  - 1
DP  - 2006 May
TI  - A prospective, multicenter, randomized, parallel-group, open-label study of 
      aripiprazole in the management of patients with schizophrenia or schizoaffective 
      disorder in general psychiatric practice: Broad Effectiveness Trial With 
      Aripiprazole (BETA).
PG  - 77-89
AB  - OBJECTIVE: BETA was designed to evaluate the overall effectiveness of 
      aripiprazole in patients with schizophrenia or schizoaffective disorder treated 
      in a general psychiatry outpatient practice setting. METHODS: In this 8-week, 
      multicenter, open-label study, 1,599 outpatients with schizophrenia or 
      schizoaffective disorder were randomly assigned to receive either aripiprazole 
      (n=1,295) or another antipsychotic medication (safety control [SC] group; n=304). 
      Aripiprazole was initiated at 15 mg/d with the option to adjust between 10-30 
      mg/d. The SC medication was specifically selected for each patient by the 
      clinician and dosed according to prescribing guidelines for that medication. The 
      primary effectiveness measure was the Clinical Global Impression-Improvement 
      (CGI-I) score of the aripiprazole group at study end point. Secondary measures 
      included response rates and preference of medicine (POM) ratings by patients and 
      caregivers. RESULTS: Sixty-five percent of aripiprazole patients completed the 
      study. The mean aripiprazole dose at end point was 19.9 mg/d, with approximately 
      39% of patients starting and remaining at 15 mg/d. At end point, the mean CGI-I 
      score of 2.77 demonstrated that aripiprazole was minimally to moderately 
      effective; the mean CGI-I score for the SC group was 3.59 indicating minimally 
      effective to no change. Fifty-three percent of aripiprazole patients responded to 
      treatment (CGI-I score of 1 or 2; last-observation-carried-forward [LOCF]), and 
      approximately 71% of patients and caregivers rated aripiprazole as better than 
      the prestudy medication on the POM (LOCF). Incidence and severity of adverse 
      events (AEs) were similar to those reported in double-blind, randomized, 
      placebo-controlled aripiprazole clinical trials. The most frequent AE in the 
      aripiprazole group was insomnia (24%). CONCLUSIONS: Aripiprazole was effective 
      for the treatment of schizophrenia and schizoaffective disorder in a general 
      psychiatry outpatient practice setting. Overall, aripiprazole was found to be 
      effective by the treating clinician and well accepted by patients and caregivers 
      over the 8-week treatment course.
FAU - Tandon, Rajiv
AU  - Tandon R
AD  - Florida Department of Children and Families, 1317 Winewood Boulevard, 
      Tallahassee, FL 32399, USA. rajiv_tandon@dcf.state.fl.us
FAU - Marcus, Ronald N
AU  - Marcus RN
FAU - Stock, Elyse G
AU  - Stock EG
FAU - Riera, Linda C
AU  - Riera LC
FAU - Kostic, Dusan
AU  - Kostic D
FAU - Pans, Miranda
AU  - Pans M
FAU - McQuade, Robert D
AU  - McQuade RD
FAU - Nyilas, Margaretta
AU  - Nyilas M
FAU - Iwamoto, Taro
AU  - Iwamoto T
FAU - Crandall, David T
AU  - Crandall DT
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
DEP - 20060214
PL  - Netherlands
TA  - Schizophr Res
JT  - Schizophrenia research
JID - 8804207
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Piperazines)
RN  - 0 (Quinolones)
RN  - 82VFR53I78 (Aripiprazole)
SB  - IM
MH  - Adult
MH  - Ambulatory Care
MH  - Antipsychotic Agents/*therapeutic use
MH  - Aripiprazole
MH  - Drug Administration Schedule
MH  - Female
MH  - Humans
MH  - Male
MH  - Piperazines/*therapeutic use
MH  - Primary Health Care/*methods
MH  - Prospective Studies
MH  - Psychiatry/*methods
MH  - Psychotic Disorders/diagnosis/*drug therapy
MH  - Quinolones/*therapeutic use
MH  - Schizophrenia/diagnosis/*drug therapy
MH  - Treatment Outcome
EDAT- 2006/02/18 09:00
MHDA- 2006/09/09 09:00
CRDT- 2006/02/18 09:00
PHST- 2005/07/11 00:00 [received]
PHST- 2005/12/27 00:00 [revised]
PHST- 2005/12/29 00:00 [accepted]
PHST- 2006/02/18 09:00 [pubmed]
PHST- 2006/09/09 09:00 [medline]
PHST- 2006/02/18 09:00 [entrez]
AID - S0920-9964(06)00014-4 [pii]
AID - 10.1016/j.schres.2005.12.857 [doi]
PST - ppublish
SO  - Schizophr Res. 2006 May;84(1):77-89. doi: 10.1016/j.schres.2005.12.857. Epub 2006 
      Feb 14.